玮俊生物科技有限公司（股票代码：00660）于2026年6月3日发布2026年5月股份变动月报表。截至2026年5月31日，公司法定注册股本维持在港币102,040,000，其中普通股10,000,000,000股、可换股优先股204,000,000股，面值均为港币0.01。
报告期内，普通股已发行股份由345,143,119股增至367,643,119股，增加22,500,000股，无库存股变动。本次增发主要来自公司部分可换股债券转换，转换后公司普通股本月底总数达到367,643,119股。
根据月报，购股权计划项下的股份期权在本月无新股发行，结存的股份期权数量保持15,954,685份，行使价为每股港币0.25。此外，公司本月未进行任何股份回购或注销活动。
公司称，所有增发及股权变动均已获得董事会正式授权，并符合香港联交所《上市规则》及相关法律规定。公告由执行董事林家俊签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.